NEW YORK (GenomeWeb News) – The Danish drug discovery firm Nuevolution said today that it will collaborate with Cancer Research Technology, the commercial branch of Cancer Research UK, to identify possible drug candidates for use in cancer treatments.

Under the collaboration, Nuevolution will use its Chemetics technology, which uses DNA labeling for small-molecule drug screening, to identify drug leads that block the activity of a number of cancer targets, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.